Kevin Kia, MD
Dermatology · Garland, TXNPI 1700088804
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $223,381 of the $270,786 with a category attached, or 82.5%. AbbVie accounts for 63.0% of it on its own, with 28 other manufacturers making up the rest. 2025 is the largest year on record at $149,923, more than ten times the $471 reported in 2019. Among dermatology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 589 payments — averaging $459.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$171K
- Galderma Laboratories, L.p.$93K
- Sanofi$2K
- UCB, Inc.$854
- Incyte Corporation$433
- Endo USA, Inc.$420
- plus $3K from 23 others
Across 25 payments — averaging $2528.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$63K
What the payments were for
- Consulting fees$6,8753%
- Speaking & faculty fees$223,38182%
- Travel & lodging$19,6557%
- Food & beverage$20,8688%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 257 | $170,663 |
| Galderma Laboratories, L.p. | 123 | $92,531 |
| Sanofi | 59 | $2,471 |
| UCB, Inc. | 14 | $854 |
| Incyte Corporation | 10 | $433 |
| Endo USA, Inc. | 1 | $420 |
| Regeneron Healthcare Solutions, Inc. | 30 | $406 |
| Chugai Pharmaceutical Co., Ltd. | 1 | $400 |
| Lilly USA, LLC | 4 | $326 |
| LEO Pharma Inc. | 13 | $306 |
| Dermavant Sciences, Inc. | 29 | $273 |
| Amgen | 6 | $239 |
| Pfizer | 3 | $179 |
| Boehringer Ingelheim | 4 | $171 |
| Organon | 14 | $169 |
| Janssen Scientific Affairs, LLC | 1 | $144 |
| E.r. Squibb & Sons, L.L.C. | 1 | $137 |
| Blueprint Medicines Corporation | 1 | $122 |
| VYNE Pharmaceuticals Inc. | 1 | $122 |
| Kyowa Kirin, Inc. | 1 | $121 |
| Novartis | 4 | $84 |
| Arcutis Biotherapeutics, Inc. | 3 | $54 |
| Sun Pharmaceutical Industries Inc. | 3 | $50 |
| Cipher Pharmaceuticals US LLC | 1 | $23 |
| Journey Medical Corporation | 1 | $22 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $19 |
| Almirall LLC | 1 | $16 |
| Botanix SB Inc | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$270,786 in reported general payments places this provider in the 95th percentile of 1,098 dermatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 42 | $841,090 |
| Dupixent PenDupilumab | 62 | $233,300 |
| RinvoqUpadacitinib | 13 | $81,158 |
| Taltz AutoinjectorIxekizumab | 12 | $80,813 |
| Clobetasol Propionate | 439 | $20,017 |
| Tacrolimus | 255 | $16,383 |
| Betamethasone Dipropionate | 260 | $11,184 |
| Minocycline Hcl | 996 | $8,764 |
| Acitretin | 22 | $8,310 |
| Ketoconazole | 524 | $7,202 |
| Mycophenolate Mofetil | 85 | $5,522 |
| Metronidazole | 103 | $4,446 |
| Tretinoin | 44 | $3,775 |
| Triamcinolone Acetonide | 371 | $3,214 |
| Fluocinonide | 82 | $3,169 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $170,663 | $81,15813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,098 dermatology providers in Texas.
Other dermatology in Garland
- Edward LainAustin$2.5M
- William CragunSan Antonio$2.2M
- Alpesh DesaiHouston$1.6M
- Craig TellerBellaire$1.3M
- Jennifer CatherDallas$1.3M
- Emily BeckerSan Antonio$1.2M
- Ross RaduskyDallas$1.2M
- Joseph MerolaDallas$1.2M
- Daniel CarrascoAustin$1.1M
- Dale SchaeferAustin$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.